Actively Recruiting
COGSCREEN II: Early Detection of Cognitive Impairment Through Screening by General Practitioners and Specialists in Older Adults in Germany
Led by Robert Perneczky · Updated on 2026-03-12
400
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
R
Robert Perneczky
Lead Sponsor
D
Davos Alzheimer's Collaborative
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are investigating the early detection of cognitive decline in older adults to better identify Alzheimer's disease (AD) at its earliest stages. The study focuses on individuals aged 60 and above who may show subjective cognitive deficits or mild cognitive impairment, which can indicate early AD. Early identification is important for dementia prevention and to prepare for future disease-modifying treatments. This project builds on a network of general practitioners and specialists to improve detection outside specialist clinics, addressing current low diagnostic rates. Participants will be involved in a randomized study comparing two groups: one receiving blood-based biomarker testing alongside digital cognitive assessments, and one without blood biomarker testing. The study introduces proprietary digital cognitive tests and blood biomarker tools to participating physicians. This approach aims to create a precision medicine model for early AD diagnosis, focusing on community-based healthcare settings. The study will last for about two years on average. During the study, researchers will monitor the percentage of participants diagnosed with Alzheimer's disease supported by blood biomarker evidence. They will also assess diagnostic costs, clinical management changes, and acceptance of screening tools by both physicians and participants. Various questionnaires, cognitive tests, and biomarker analyses will be used to evaluate the effectiveness and user experience of the screening methods throughout the study duration.
CONDITIONS
Brief Title
COGSCREEN II: Early Detection of Cognitive Impairment
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female 60 years of age or older at the time of consent
- Able to understand and voluntarily sign an informed consent according to the judgment of the practice team
You will not qualify if you...
- Unable to hear or see well enough to complete the assessments
- Prior diagnosis of dementia documented in medical records or by a physician diagnosis with or without pathology evidence
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Approximately 2 years
Participants undergo observation with or without blood-based biomarker testing to detect early cognitive impairment over approximately 2 years.
Trial Site Locations
Total: 1 location
1
Klinik für Psychiatrie und Psychotherapie am LMU Klinikum
München, Germany, 80336
Actively Recruiting
Research Team
P
Prof. Dr. Robert Perneczky
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SCREENING
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here